Hemogenyx Pharmaceuticals (LON:HEMO) Releases Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) released its quarterly earnings results on Monday. The company reported GBX (101.70) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Performance

Shares of HEMO opened at GBX 478.43 on Wednesday. Hemogenyx Pharmaceuticals has a 1 year low of GBX 356 and a 1 year high of GBX 1,330. The company’s 50 day simple moving average is GBX 568.56 and its 200 day simple moving average is GBX 729.45. The company has a market capitalization of £32.53 million, a price-to-earnings ratio of -2.80 and a beta of 1.49. The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.